Interleukin-10 inhibits the immune stimulatory potential of melanoma cells retrovirally transduced with human B7.1 or B7.2

Advances in Experimental Medicine and Biology

Volumn 451, Issue , 1998, Pages 179-188

  Geertsen, R ^a,c   Yue, F Y ^a   Pavlovic, J ^b   Laine, E ^a   Dummer, R ^a  

^a Department of Dermatology ^*  (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; INTERLEUKIN 10;

ANTIGEN EXPRESSION; ARTICLE; CELL PROLIFERATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MELANOMA; PRIORITY JOURNAL; RETROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION;

EID: 0031723627     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-5357-1_29     Document Type: Article

References (32)

1. J.C. Bystryn, 1989; Immunosurveillance and melanoma. J Invest Dermatol 92, S318-320
2. R. Zakut, S.L. Topalian, Y. Kawakami, M. Mancini, S. Eliyahu and S.A. Rosenberg, 1993; Differential expression of MAGE-1, -2, and -3 messenger RNA in transformed and normal human cell lines. Cancer Res 53, 5-8
3. A.B. Bakker, M.W. Schreurs, B.A. de, Y. Kawakami, S.A. Rosenberg, G.J. Adema and C.G. Figdor, 1994; Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 179, 1005-1009
4. Y. Kawakami, S. Eliyahu, K. Sakaguchi, P.F. Robbins, L. Rivoltini, J.R. Yannelli, E. Appella and S.A. Rosenberg, 1994; Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 180, 347-52
5. J.C. Becker, T. Brabletz, C. Czerny, C. Termeer and E.B. Brocker, 1993; Tumor escape mechanisms from immunosurveillance: induction of unresponsiveness in a specific MHC-restricted CD4+ human T cell clone by the autologous MHC class 11+ melanoma. Int Immunol 5, 1501-8
6. G.J. Freeman, J.G. Gribben, V.A. Boussiotis, J.W. Ng, V.J. Restivo, L.A. Lombard, G.S. Gray and L.M. Nadler, 1993; Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation [see comments]. Science 262, 909-11
7. E.C. Guinan, J.G. Gribben, V.A. Boussiotis, G.J. Freeman and L.M. Nadler, 1994; Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 84, 3261-82
8. C. Döhring, L. Angman, G. Spagnoli and A. Lanzavecchia, 1994; T-helper- and accessory-cell-independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector. Int J Cancer 57, 754-9
9. S.E. Townsend and J.P. Allison, 1993; Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259, 368-70
10. Y. Li, P. McGowan, I. Hellstrom, K.E. Hellstrom and L. Chen, 1994; Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol 153, 421-8
11. R.W. Denfeld, A. Dietrich, C. Wuttig, E. Tanczos, J.M. Weiss, W. Vanscheidt, E. Schopf and J.C. Simon, 1995; In situ expression of B7 and CD28 receptor families in human malignant melanoma: relevance for T-cell-mediated anti-tumor immunity. Int J Cancer 62, 259-65
12. R.T. Fenton, M. Sznol, D.G. Luster, D.D. Taub and D.L. Longo, 1995; A phase I trial of B7-transfected parental lethally irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-A1 in patients with stage IV melanoma. NCI protocol T93-0161. BRMP protocol 9401. Hum Gene Ther 6, 87-106
13. J.C. Becker, A. Schwinn, R. Dummer, G. Burg and E.B. Brocker, 1993; Lesion-specific activation of cloned human tumor-infiltrating lymphocytes by autologous tumor cells: induction of proliferation and cytokine production. J Invest Dermatol 101, 15-21
14. A.D. Miller and G.J. Rosman, 1989; Improved retroviral vectors for gene transfer and expression. Biotechniques 7, 980-990
15. D. Markowitz, S. Goff and A. Bank, 1988; A safe packaging line for gene transfer: separating viral genes on two different plasmids. J Virol 62, 1120-4
16. P. Vieira, R. de Waal-Malefyt, M.N. Dang, K.E. Johnson, R. Kastelein, D.F. Fiorentino, J.E. deVries, M.G. Roncarolo, T.R. Mosmann and K.W. Moore, 1991; Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci U S A 88, 1172-6
17. S. Altschul, W. Gish, W. Miller, E. Myers and D. Lipman, 1990; Basic local alignment search tool. J Mol Biol 215, 403-10
18. F.V. Cromme, P.F. van Bommel, J.M. Walboomers, M.P. Gallee, P.L. Stern, P. Kenemans, T.J. Helmerhorst, M.J. Stukart and C.J. Meijer, 1994; Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br J Cancer 69, 1176-81
19. R. Dummer and R. Boni, 1995; Wie entkommen Melanomzellen der Immunantwort? Konsequenzen fur zukunftige Therapieansatze und gegenwartige Biopsieverarbeitung. Schweiz Med Wochenschr 125, 1638-41
20. J. Sule-Suso, F. Arienti, C. Melani, M.P. Colombo and G. Parmiani, 1995; A B7-1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes. Eur J Immunol 25, 2737-42
21. G.J. Freeman, V.A. Boussiotis, A. Anumanthan, G.M. Bernstein, X.Y. Ke, P.D. Rennert, G.S. Gray, J.G. Gribben and L.M. Nadler, 1995; B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 2, 523-32
22. V.K. Kuchroo, M.P. Das, J.A. Brown, A.M. Ranger, S.S. Zamvil, R.A. Sobel, H.L. Weiner, N. Nabavi and L.H. Glimcher, 1995; B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80, 707-18
23. L.L. Lanier, S. O'Fallon, C. Somoza, J.H. Phillips, P.S. Linsley, K. Okumura, D. Ito and M. Azuma, 1995; CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J Immunol 154, 97-105
24. T.F. Gajewski, F. Fallarino, C. Uyttenhove and T. Boon, 1996; Tumor Rejection Requires a Ctla4 Ligand Provided By the Host or Expressed On the Tumor - Superiority Of B7-1 Over B7-2 For Active Tumor Immunization. Journal of Immunology 156, 2909-2917
25. J.C. Becker, C. Czerny and E.B. Brocker, 1994; Maintenance of clonal anergy by endogenously produced IL-10. Int Immunol 6, 1605-12
26. S. Kruger-Krasagakes, K. Krasagakis, C. Garbe and T. Diamantstein, 1995; Production of cytokines by human melanoma cells and melanocytes. Recent Results Cancer Res 139, 155-68
27. S. Mattei, M.P. Colombo, C. Melani, A. Silvani, G. Parmiani and M. Herlyn, 1994; Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer 56, 853-7
28. Q. Chen, V. Daniel, D.W. Maher and P. Hersey, 1994; Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer 56, 755-60
29. F.Y. Yue, R. Dummer, R. Geertsen, G. Hofbauer, E. Laine, S. Manolio and G. Burg, 1997; Interleukin-10 Is a Growth Factor For Human Melanoma Cells and Down-Regulates Hla Class-I, Hla Class-Ii and Icam-I Molecules. International Journal of Cancer 71, 630-637
30. R. deWaal Malefyt, H. Yssel and V.J. de, 1993; Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J Immunol 150, 4754-65
31. M. Howard and A. O'Garra, 1992; Biological properties of interleukin 10. Immunol Today 13, 198-200
32. M. Matsuda, F. Salazar, M. Petersson, G. Masucci, J. Hansson, P. Pisa, Q.J. Zhang, M.G. Masucci and R. Kiessling, 1994; Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 180, 2371-6